Top

Published in:

Open Access 01-12-2016 | Review

CXCL14 as an emerging immune and inflammatory modulator

Authors: Jing Lu, Mita Chatterjee, Hannes Schmid, Sandra Beck, Meinrad Gawaz

Published in: Journal of Inflammation | Issue 1/2016

Abstract

CXCL14, a relatively novel chemokine, is a non-ELR (glutamic acid-leucine-arginine) chemokine with a broad spectrum of biological activities. CXCL14 mainly contributes to the regulation of immune cell migration, also executes antimicrobial immunity. The identity of the receptor for CXCL14 still remains obscure and therefore the intracellular signaling pathway is not entirely delineated. The present review summarizes the contribution of CXCL14 in these two aspects and discusses the biological mechanisms regulating CXCL14 expression and potential CXCL14 mediated functional implications in a variety of cells.

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedCrossRef

Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75–84.PubMedCrossRef

Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006;7:243.PubMedPubMedCentralCrossRef

Frick IM, Nordin SL, Baumgarten M, Morgelin M, Sorensen OE, Olin AI, et al. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes. J Immunol. 2011;187:4300–9.PubMedCrossRef

Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson KN, Azam M, et al. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999;255:703–6.PubMedCrossRef

Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol. 2000;156:1937–50.PubMedPubMedCentralCrossRef

Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol. 2000;12:677–89.PubMedCrossRef

Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, et al. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. Vol. 2000;165:2588–95.

Huising MO, van der Meulen T, Flik G, Verburg-van KB. Three novel carp CXC chemokines are expressed early in ontogeny and at nonimmune sites. Eur J Biochem. 2004;271:4094–106.PubMedCrossRef

10.

Clark-Lewis I, Dewald B, Loetscher M, Moser B, Baggiolini M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J Biol Chem. 1994;269:16075–81.PubMed

11.

Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity. Biosci Rep. 2006;26:325–39.PubMedPubMedCentralCrossRef

12.

Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome. J Mol Biol. 2006;363:813–22.PubMedPubMedCentralCrossRef

13.

Salogni L, Musso T, Bosisio D, Mirolo M, Jala VR, Haribabu B, et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood. 2009;113:5848–56.PubMedCrossRef

14.

Maerki C, Meuter S, Liebi M, Muhlemann K, Frederick MJ, Yawalkar N, et al. Potent and broad-spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections. J Immunol. 2009;182:507–14.PubMedCrossRef

15.

Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001;194:855–61.PubMedPubMedCentralCrossRef

16.

Schaerli P, Willimann K, Ebert LM, Walz A, Moser B. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity. 2005;23:331–42.PubMedCrossRef

17.

Hevezi P, Moyer BD, Lu M, Gao N, White E, Echeverri F, et al. Genome-wide analysis of gene expression in primate taste buds reveals links to diverse processes. PLoS One. 2009;4:e6395.PubMedPubMedCentralCrossRef

18.

Dawes C, Pedersen AM, Villa A, Ekstrom J, Proctor GB, Vissink A, et al. The functions of human saliva: a review sponsored by the world workshop on oral medicine VI. Arch Oral Biol. 2015;60:863–74.PubMedCrossRef

19.

Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004;64:8262–70.PubMedCrossRef

20.

Parsanejad R, Fields WR, Steichen TJ, Bombick BR, Doolittle DJ. Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J Interferon Cytokine Res. 2008;28:703–12.PubMedCrossRef

21.

Lindberg J, Af KE, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther. 2006;8:R179.PubMedPubMedCentralCrossRef

22.

Chen L, Guo L, Tian J, He H, Marinova E, Zhang P, et al. Overexpression of CXC chemokine ligand 14 exacerbates collagen-induced arthritis. J Immunol. 2010;184:4455–9.PubMedPubMedCentralCrossRef

23.

Padilla J, Jenkins NT, Lee S, Zhang H, Cui J, Zuidema MY, et al. Vascular transcriptional alterations produced by juvenile obesity in Ossabaw swine. Physiol Genomics. 2013;45:434–46.PubMedPubMedCentralCrossRef

24.

Egesten A, Olin AI, Linge HM, Yadav M, Morgelin M, Karlsson A, et al. SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines. PLoS One. 2009;4:e4769.PubMedPubMedCentralCrossRef

25.

Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A. 2002;99:13647–52.PubMedPubMedCentralCrossRef

26.

McKinnon CM, Lygoe KA, Skelton L, Mitter R, Mellor H. The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells. Oncogene. 2008;27:6856–65.PubMedCrossRef

27.

Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res. 2009;69:2375–83.PubMedPubMedCentralCrossRef

28.

Ozawa S, Ito S, Kato Y, Kubota E, Hata R. Human p38 delta MAP kinase mediates UV irradiation induced up-regulation of the gene expression of chemokine BRAK/CXCL14. Biochem Biophys Res Commun. 2010;396:1060–4.PubMedCrossRef

29.

Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, Hata R. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun. 2006;348:406–12.PubMedCrossRef

30.

Ito S, Ozawa S, Ikoma T, Yajima N, Kiyono T, Hata R. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res. 2010;31:199–206.PubMedCrossRef

31.

Efimova T, Broome AM, Eckert RL. A regulatory role for p38 delta MAPK in keratinocyte differentiation. Evidence for p38 delta-ERK1/2 complex formation. J Biol Chem. 2003;278:34277–85.PubMedCrossRef

32.

Park CR, You DJ, Kim DK, Moon MJ, Lee C, Oh SH, et al. CXCL14 enhances proliferation and migration of NCI-H460 human lung cancer cells overexpressing the glycoproteins containing heparan sulfate or sialic acid. J Cell Biochem. 2013;114:1084–96.PubMedCrossRef

33.

Hu C, Lin F, Zhu G, Xue X, Ding Y, Zhao Z, et al. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer. Int J Oncol. 2013;43:1487–94.PubMed

34.

Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A. 2009;106:3414–9.PubMedPubMedCentralCrossRef

35.

Augsten M, Sjoberg E, Frings O, Vorrink SU, Frijhoff J, Olsson E, et al. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014;74:2999–3010.PubMedCrossRef

36.

Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 2008;259:209–17.PubMedCrossRef

37.

Miyamoto C, Maehata Y, Motohashi K, Ozawa S, Ikoma T, Hidaka K, et al. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma. Biomed Res. 2014;35:381–8.PubMedCrossRef

38.

Lyu XJ, Li HZ, Ma X, Li XT, Gao Y, Ni D, et al. Elevated S100A6 (Calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma. Oncotarget. 2015;6:6656–69.PubMedPubMedCentralCrossRef

39.

Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z, et al. IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-kappaB signaling. J Clin Invest. 2015;125:1839–56.PubMedPubMedCentralCrossRef

40.

Tanegashima K, Suzuki K, Nakayama Y, Tsuji K, Shigenaga A, Otaka A, et al. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett. 2013;587:1731–5.PubMedCrossRef

41.

Tanegashima K, Tsuji K, Suzuki K, Shigenaga A, Otaka A, Hara T. Dimeric peptides of the C-terminal region of CXCL14 function as CXCL12 inhibitors. FEBS Lett. 2013;587:3770–5.PubMedCrossRef

42.

Tsuji K, Tanegashima K, Sato K, Sakamoto K, Shigenaga A, Inokuma T, et al. Efficient one-pot synthesis of CXCL14 and its derivative using an N-sulfanylethylanilide peptide as a peptide thioester equivalent and their biological evaluation. Bioorg Med Chem. 2015;23:5909–14.PubMedCrossRef

43.

Hayashi Y, Murakami M, Kawamura R, Ishizaka R, Fukuta O, Nakashima M. CXCL14 and MCP1 are potent trophic factors associated with cell migration and angiogenesis leading to higher regenerative potential of dental pulp side population cells. Stem Cell Res Ther. 2015;6:111.PubMedPubMedCentralCrossRef

44.

Iohara K, Zheng L, Wake H, Ito M, Nabekura J, Wakita H, et al. A novel stem cell source for vasculogenesis in ischemia: subfraction of side population cells from dental pulp. Stem Cells. 2008;26:2408–18.PubMedCrossRef

45.

Mokhtar NM, Cheng CW, Cook E, Bielby H, Smith SK, Charnock-Jones DS. Progestin regulates chemokine (C-X-C motif) ligand 14 transcript level in human endometrium. Mol Hum Reprod. 2010;16:170–7.PubMedCrossRef

46.

Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101–9.PubMedCrossRef

47.

Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 2006;34:1101–5.PubMedCrossRef

48.

Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490–8.PubMedCrossRef

49.

Meuter S, Schaerli P, Roos RS, Brandau O, Bosl MR, von Andrian UH, et al. Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues. Mol Cell Biol. 2007;27:983–92.PubMedPubMedCentralCrossRef

50.

Cao Q, Chen H, Deng Z, Yue J, Chen Q, Cao Y, et al. Genetic deletion of Cxcl14 in mice alters uterine NK cells. Biochem Biophys Res Commun. 2013;435:664–70.PubMedCrossRef

51.

DeVries ME, Kelvin AA, Xu L, Ran L, Robinson J, Kelvin DJ. Defining the origins and evolution of the chemokine/chemokine receptor system. J Immunol. 2006;176:401–15.PubMedCrossRef

52.

Huising MO, Stet RJ, Kruiswijk CP, Savelkoul HF, Lidy VKB. Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol. 2003;24:307–13.PubMed

53.

Garcia-Andres C, Torres M. Comparative expression pattern analysis of the highly conserved chemokines SDF1 and CXCL14 during amniote embryonic development. Dev Dyn. 2010;239:2769–77.PubMedCrossRef

54.

Otte M, Kliewer A, Schutz D, Reimann C, Schulz S, Stumm R. CXCL14 is no direct modulator of CXCR4. FEBS Lett. 2014;588:4769–75.PubMedCrossRef

55.

Schroder JM, Harder J. Antimicrobial skin peptides and proteins. Cell Mol Life Sci. 2006;63:469–86.PubMedCrossRef

56.

Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol. 2005;125:9–13.PubMedCrossRef

57.

Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol. 2006;18:24–30.PubMedCrossRef

58.

Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–20.PubMedCrossRef

59.

Izadpanah A, Gallo RL. Antimicrobial peptides. J Am Acad Dermatol. 2005;52:381–90. quiz 391–2.PubMedCrossRef

60.

Wolf M, Moser B. Antimicrobial activities of chemokines: not just a side-effect? Front Immunol. 2012;3:213.PubMedPubMedCentralCrossRef

61.

Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol. 2003;74:448–55.PubMedCrossRef

62.

Dai C, Basilico P, Cremona TP, Collins P, Moser B, Benarafa C, et al. CXCL14 displays antimicrobial activity against respiratory tract bacteria and contributes to clearance of Streptococcus pneumoniae pulmonary infection. J Immunol. 2015;194:5980–9.PubMedCrossRef

63.

Kovach MA, Ballinger MN, Newstead MW, Zeng X, Bhan U, Yu FS, et al. Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J Immunol. 2012;189:304–11.PubMedPubMedCentralCrossRef

64.

Tanegashima K, Suzuki K, Nakayama Y, Hara T. Antibody-assisted enhancement of biological activities of CXCL14 in human monocytic leukemia-derived THP-1 cells and high fat diet-induced obese mice. Exp Cell Res. 2010;316:1263–70.PubMedCrossRef

65.

Booth V, Clark-Lewis I, Sykes BD. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC). Protein Sci. 2004;13:2022–8.PubMedPubMedCentralCrossRef

66.

Veldkamp CT, Ziarek JJ, Su J, Basnet H, Lennertz R, Weiner JJ, et al. Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci. 2009;18:1359–69.PubMedPubMedCentralCrossRef

67.

Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular systems biology. 2011;7:539. PMID: 21988835.PubMedPubMedCentralCrossRef

Title: CXCL14 as an emerging immune and inflammatory modulator
Authors: Jing Lu
Mita Chatterjee
Hannes Schmid
Sandra Beck
Meinrad Gawaz
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Inflammation / Issue 1/2016
Electronic ISSN: 1476-9255
DOI: https://doi.org/10.1186/s12950-015-0109-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

CXCL14 as an emerging immune and inflammatory modulator

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells

ERK2 and Akt are negative regulators of insulin and Tumor Necrosis Factor-α stimulated VCAM-1 expression in rat aorta endothelial cells

Nur77-mediated TRAF6 signalling protects against LPS-induced sepsis in mice

The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets

Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment

Lipopolysaccharide-induced inflammation or unilateral ureteral obstruction yielded multiple types of glycosylated Lipocalin 2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page